Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Dec 6;6(1):417.
doi: 10.1038/s41392-021-00813-y.

First-line anti-VEGF plus EGFR-TKI in EGFR-mutant NSCLC: adding the ARTEMIS trial to the puzzle of current evidence

Susanne Hafner  1
Affiliations
Comment

First-line anti-VEGF plus EGFR-TKI in EGFR-mutant NSCLC: adding the ARTEMIS trial to the puzzle of current evidence

Susanne Hafner. Signal Transduct Target Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The author declares no competing interests.

Figures

Fig. 1
Fig. 1. Clinical trials of EGFR-TKI and Anti-VEGF as first-line treatment in advanced EGFR-mutant NSCLC.
a Overview on the completed and ongoing clinical trials of EGFR-TKI and Anti-VEGF as first-line treatment in advanced EGFR-mutant NSCLC. Modified and updated from: Chen et al. 2020; data were extracted from the indexed publications and/or publically available clinical trial databases; bold values indicate significant differences; grey and yellow colors highlight study data for PFS and OS with erlotinib and erlotinib+bevacizumab treatment, which are illustrated in (b). *Data presented at the European Society for Medical Oncology (ESMO) Conference, September 2021; PFS refers to investigator-assessed PFS in the BEVERLY trial and blinded independent radiologic reviewer-assessed PFS in the WJOG8717L trial, respectively. EGFR epidermal growth factor receptor, PFS progression-free survival, ORR objective response rate, OS overall survival, n.r. not reported, TKI tyrosine kinase inhibitor–. b Progression-free survival (left panel) and overall survival (right panel) in prospective phase 2 and 3 clinical trials of EGFR-TKI erlotinib and bevacizumab as first-line treatment in advanced EGFR-mutant NSCLC.
See this image and copyright information in PMC

Comment on

References

    1. Zhou, Q. et al. Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): a multicenter phase 3 study. Cancer Cell39, 1279–1291.e1273 (2021). - PubMed
    1. Seto T, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014;15:1236–1244. doi: 10.1016/S1470-2045(14)70381-X. - DOI - PubMed
    1. Saito H, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019;20:625–635. doi: 10.1016/S1470-2045(19)30035-X. - DOI - PubMed
    1. Stinchcombe TE, et al. Effect of erlotinib plus bevacizumab vs erlotinib alone on progression-free survival in patients with advanced EGFR-mutant non-small cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2019;5:1448–1455. doi: 10.1001/jamaoncol.2019.1847. - DOI - PMC - PubMed
    1. Chen F, Chen N, Yu Y, Cui J. Efficacy and safety of epidermal growth factor receptor (EGFR) inhibitors plus antiangiogenic agents as first-line treatments for patients with advanced EGFR-mutated non-small cell lung cancer: a meta-analysis. Front. Oncol. 2020;10:904. doi: 10.3389/fonc.2020.00904. - DOI - PMC - PubMed

MeSH terms